242 related articles for article (PubMed ID: 30530501)
21. The dystonia gene THAP1 controls DNA double-strand break repair choice.
Shinoda K; Zong D; Callen E; Wu W; Dumitrache LC; Belinky F; Chari R; Wong N; Ishikawa M; Stanlie A; Multhaupt-Buell T; Sharma N; Ozelius L; Ehrlich M; McKinnon PJ; Nussenzweig A
Mol Cell; 2021 Jun; 81(12):2611-2624.e10. PubMed ID: 33857404
[TBL] [Abstract][Full Text] [Related]
22. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
23. The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Barazas M; Annunziato S; Pettitt SJ; de Krijger I; Ghezraoui H; Roobol SJ; Lutz C; Frankum J; Song FF; Brough R; Evers B; Gogola E; Bhin J; van de Ven M; van Gent DC; Jacobs JJL; Chapman R; Lord CJ; Jonkers J; Rottenberg S
Cell Rep; 2018 May; 23(7):2107-2118. PubMed ID: 29768208
[TBL] [Abstract][Full Text] [Related]
24. The shieldin complex mediates 53BP1-dependent DNA repair.
Noordermeer SM; Adam S; Setiaputra D; Barazas M; Pettitt SJ; Ling AK; Olivieri M; Álvarez-Quilón A; Moatti N; Zimmermann M; Annunziato S; Krastev DB; Song F; Brandsma I; Frankum J; Brough R; Sherker A; Landry S; Szilard RK; Munro MM; McEwan A; Goullet de Rugy T; Lin ZY; Hart T; Moffat J; Gingras AC; Martin A; van Attikum H; Jonkers J; Lord CJ; Rottenberg S; Durocher D
Nature; 2018 Aug; 560(7716):117-121. PubMed ID: 30022168
[TBL] [Abstract][Full Text] [Related]
25. The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Tarsounas M; Sung P
Nat Rev Mol Cell Biol; 2020 May; 21(5):284-299. PubMed ID: 32094664
[TBL] [Abstract][Full Text] [Related]
26. Multi-omics analysis reveals distinct non-reversion mechanisms of PARPi resistance in BRCA1- versus BRCA2-deficient mammary tumors.
Bhin J; Paes Dias M; Gogola E; Rolfs F; Piersma SR; de Bruijn R; de Ruiter JR; van den Broek B; Duarte AA; Sol W; van der Heijden I; Andronikou C; Kaiponen TS; Bakker L; Lieftink C; Morris B; Beijersbergen RL; van de Ven M; Jimenez CR; Wessels LFA; Rottenberg S; Jonkers J
Cell Rep; 2023 May; 42(5):112538. PubMed ID: 37209095
[TBL] [Abstract][Full Text] [Related]
27. SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.
Findlay S; Heath J; Luo VM; Malina A; Morin T; Coulombe Y; Djerir B; Li Z; Samiei A; Simo-Cheyou E; Karam M; Bagci H; Rahat D; Grapton D; Lavoie EG; Dove C; Khaled H; Kuasne H; Mann KK; Klein KO; Greenwood CM; Tabach Y; Park M; Côté JF; Masson JY; Maréchal A; Orthwein A
EMBO J; 2018 Sep; 37(18):. PubMed ID: 30154076
[TBL] [Abstract][Full Text] [Related]
28. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
29. Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Giovannini S; Weller MC; Repmann S; Moch H; Jiricny J
Nucleic Acids Res; 2019 Sep; 47(17):9132-9143. PubMed ID: 31329989
[TBL] [Abstract][Full Text] [Related]
30. Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
Zimmer J; Tacconi EMC; Folio C; Badie S; Porru M; Klare K; Tumiati M; Markkanen E; Halder S; Ryan A; Jackson SP; Ramadan K; Kuznetsov SG; Biroccio A; Sale JE; Tarsounas M
Mol Cell; 2016 Feb; 61(3):449-460. PubMed ID: 26748828
[TBL] [Abstract][Full Text] [Related]
31. BRCA1 Directs the Repair Pathway to Homologous Recombination by Promoting 53BP1 Dephosphorylation.
Isono M; Niimi A; Oike T; Hagiwara Y; Sato H; Sekine R; Yoshida Y; Isobe SY; Obuse C; Nishi R; Petricci E; Nakada S; Nakano T; Shibata A
Cell Rep; 2017 Jan; 18(2):520-532. PubMed ID: 28076794
[TBL] [Abstract][Full Text] [Related]
32. CtIP-mediated resection is essential for viability and can operate independently of BRCA1.
Polato F; Callen E; Wong N; Faryabi R; Bunting S; Chen HT; Kozak M; Kruhlak MJ; Reczek CR; Lee WH; Ludwig T; Baer R; Feigenbaum L; Jackson S; Nussenzweig A
J Exp Med; 2014 Jun; 211(6):1027-36. PubMed ID: 24842372
[TBL] [Abstract][Full Text] [Related]
33. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Cong K; Peng M; Kousholt AN; Lee WTC; Lee S; Nayak S; Krais J; VanderVere-Carozza PS; Pawelczak KS; Calvo J; Panzarino NJ; Turchi JJ; Johnson N; Jonkers J; Rothenberg E; Cantor SB
Mol Cell; 2021 Aug; 81(15):3128-3144.e7. PubMed ID: 34216544
[TBL] [Abstract][Full Text] [Related]
34. Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
van de Ven M; van der Burg E; van der Gulden H; Klarenbeek S; Bouwman P; Jonkers J
J Pathol; 2017 Mar; 241(4):511-521. PubMed ID: 27943283
[TBL] [Abstract][Full Text] [Related]
35. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
36. Regulation of DNA repair in the absence of classical non-homologous end joining.
Kang YJ; Yan CT
DNA Repair (Amst); 2018 Aug; 68():34-40. PubMed ID: 29929045
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity and Clonal Evolution of Acquired PARP Inhibitor Resistance in
Färkkilä A; Rodríguez A; Oikkonen J; Gulhan DC; Nguyen H; Domínguez J; Ramos S; Mills CE; Pérez-Villatoro F; Lazaro JB; Zhou J; Clairmont CS; Moreau LA; Park PJ; Sorger PK; Hautaniemi S; Frias S; D'Andrea AD
Cancer Res; 2021 May; 81(10):2774-2787. PubMed ID: 33514515
[TBL] [Abstract][Full Text] [Related]
38. PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Li H; Liu ZY; Wu N; Chen YC; Cheng Q; Wang J
Mol Cancer; 2020 Jun; 19(1):107. PubMed ID: 32563252
[TBL] [Abstract][Full Text] [Related]
39. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
Wang YT; Yuan B; Chen HD; Xu L; Tian YN; Zhang A; He JX; Miao ZH
Cancer Sci; 2018 Mar; 109(3):821-831. PubMed ID: 29274141
[TBL] [Abstract][Full Text] [Related]
40. Replication fork stability confers chemoresistance in BRCA-deficient cells.
Ray Chaudhuri A; Callen E; Ding X; Gogola E; Duarte AA; Lee JE; Wong N; Lafarga V; Calvo JA; Panzarino NJ; John S; Day A; Crespo AV; Shen B; Starnes LM; de Ruiter JR; Daniel JA; Konstantinopoulos PA; Cortez D; Cantor SB; Fernandez-Capetillo O; Ge K; Jonkers J; Rottenberg S; Sharan SK; Nussenzweig A
Nature; 2016 Jul; 535(7612):382-7. PubMed ID: 27443740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]